國際醫學(000516.SZ)擬推不超766.2313萬股的2022年限制性股票激勵計劃
格隆匯9月6日丨國際醫學(000516.SZ)發佈2022年限制性股票激勵計劃(草案),擬向激勵對象授予不超過766.2313萬股限制性股票,約佔草案公吿時公司股本總額的0.34%。該計劃採取的激勵工具為限制性股票。
該計劃股票來源為公司已從二級市場回購的公司766.2313萬股A股普通股。
限制性股票授予價格為5.86元/股。該計劃擬授予激勵對象不超過138人,為公司董事會認為應當激勵的核心技術(業務)人員及其他管理骨幹,其中,核心技術(業務)人員主要為公司各醫院的醫療專家等,核心技術(業務)人員獲授的數量佔本次授予限制性股票總數的84.88%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.